Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Study of Neural Progenitor Cell Transplantation and Paracrine Factors From Human Mesenchymal Stem Cells to Treat Newborn With Hypoxic-ischemic Encephalopathy

NCT02854579 is registered in ClinicalTrials.gov with Navy General Hospital, Beijing as lead sponsor.

NCT NCT02854579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02854579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Study of Neural Progenitor Cell Transplantation and Paracrine Factors From Human Mesenchymal Stem Cells to Treat Newborn With Hypoxic-ischemic Encephalopathy
Lead sponsor
Navy General Hospital, Beijing
Phase
Not applicable
Overall status
Unknown status
Start date
January 31, 2013
Completion date
December 31, 2017
Enrollment
120 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypoxic-ischemic encephalopathy